ArticleClinicoEconomics and outcomes research : CEOR2018

Cost-consequence model comparing eltrombopag versus romiplostim for adult patients with chronic immune thrombocytopenia.

Gabriel Tremblay et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.